Skip to content
Triangle logo TriangleGet started
← Study library

NCT02196168 · REGISTRY CONDITION SEARCH

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2017-05-03

This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body. Drugs used in chemotherapy, such as cisplatin, may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA), which in turn stops the tumor from growing. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cisplatin is more effective with or without WEE1 inhibitor MK-1775 in treating patients with head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate (Complete Plus Partial Response) Using RECIST Criteria v1.1

→

outcome · POSTED

Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

→

outcome · POSTED

Levels of Pharmacodynamic Biomarkers

→

outcome · POSTED

Levels of Predictive Biomarkers

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and not amendable to curative therapy by surgery or radiation; SCCHN originating from the following sites are eligible: oral cavity, oropharynx, larynx, hypopharynx and paranasal sinus; for patients with a diagnosis of SCCHN of unknown origin, their eligibility must be reviewed and approved by the principal investigator * No prior systemic chemotherapy or WEE1 kinase inhibitor therapy for metastatic or recurrent disease will be allowed; patients are permitted to have received prior systemic chemotherapy as a part of the initial multimodality treatment for locally advanced disease if this treatment was completed more than 6 months prior to enrollment * Patients must have disease amenable to biopsy and must be medically fit to undergo a biopsy * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 10 mm with computed tomography (CT) scan; indicator lesions must not have been previously treated with surgery, radiation therapy or radiofrequency ablation unless there is documented progression after therapy * Patients must have completed any previous surgery or radiotherapy \>= 4 weeks prior to enrollment * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky \> 60%) * Life expectancy of greater than 12 weeks * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 9 g/dL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 × institutional upper limit of normal * Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =\< 1.5 upper limit of normal (ULN) * Creatinine within normal institutional limits OR calculated creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with levels above institutional normal using modified Cockcroft-Gault * Cardiac function: 12-lead electrocardiogram (ECG) with normal tracing, or non-clinically significant changes that do not require medical intervention; corrected QT (QTc) interval is to be \< 470 msec * Women of childbearing potential and men must be surgically sterilized, practicing abstinence, or agree to use 2 birth control methods prior to study entry and for the duration of study participation including up to 30 days after the last dose of MK-1775; the 2 methods of birth control can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy; the following are considered adequate barrier methods of contraception: diaphragm or sponge, and condom; other methods of contraception such as copper intrauterine device or spermicide may be used; appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents); should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Past or current malignancy other than SCCHN, except for: * Cervical carcinoma stage 1B or less * Non-invasive basal cell and squamous cell skin carcinoma * Malignant melanoma with a complete response of a duration of \> 10 years * Radically treated prostate cancer (prostatectomy or radiotherapy) with normal prostate specific antigen (PSA), and not requiring ongoing anti-androgen hormonal therapy * Other cancer diagnosis with a complete response of duration of \> 5 years * Patients may not be receiving any other investigational agents * Patients with known brain metastases should be excluded from this clinical trial * History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-1775 or cisplatin * Patients who are unable to take oral medications and/or who have a clinical or radiological diagnosis of bowel obstruction are ineligible * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, active peptic ulcer disease, myocardial infarction within 6 months prior to entry, congestive heart failure, symptomatic congestive heart failure, active cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-1775 * Human immunodeficiency virus (HIV)-positive patients are ineligible * Patients taking the following prescription or non-prescription drugs or other products (i.e. grapefruit juice) are ineligible: sensitive cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates, CYP3A4 substrates with a narrow therapeutic index, moderate to potent inhibitors/inducers of CYP3A4; patients would be eligible if the medications can be discontinued two weeks prior to day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication
healthy Volunteers
false
minimum Age
19 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
    intervention Names
    1. Drug: Cisplatin
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    4. Drug: WEE1 Inhibitor AZD1775
    label
    Arm I (WEE1 inhibitor MK-1775, cisplatin)
    type
    EXPERIMENTAL
  2. description
    Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
    intervention Names
    1. Drug: Cisplatin
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    4. Other: Placebo
    label
    Arm II (placebo, cisplatin)
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm I (WEE1 inhibitor MK-1775, cisplatin)
    2. Arm II (placebo, cisplatin)
    description
    Given IV
    name
    Cisplatin
    other Names
    1. Abiplatin
    2. Blastolem
    3. Briplatin
    4. CDDP
    5. Cis-diammine-dichloroplatinum
    6. Cis-diamminedichloridoplatinum
    7. Cis-diamminedichloro Platinum (II)
    8. Cis-diamminedichloroplatinum
    9. Cis-dichloroammine Platinum (II)
    10. Cis-platinous Diamine Dichloride
    11. Cis-platinum
    12. Cis-platinum II
    type
    DRUG
  2. arm Group Labels
    1. Arm I (WEE1 inhibitor MK-1775, cisplatin)
    2. Arm II (placebo, cisplatin)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Arm I (WEE1 inhibitor MK-1775, cisplatin)
    2. Arm II (placebo, cisplatin)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
  4. arm Group Labels
    1. Arm II (placebo, cisplatin)
    description
    Given PO
    name
    Placebo
    other Names
    1. placebo therapy
    2. PLCB
    3. sham therapy
    type
    OTHER
  5. arm Group Labels
    1. Arm I (WEE1 inhibitor MK-1775, cisplatin)
    description
    Given PO
    name
    WEE1 Inhibitor AZD1775
    other Names
    1. AZD-1775
    2. AZD1775
    3. MK-1775
    4. MK1775
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
TRIPLE
who Masked
  1. PARTICIPANT
  2. CARE_PROVIDER
  3. INVESTIGATOR
primary Purpose
TREATMENT
Enrollment
count
6
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Per Response Evaluation Criteria in solid Tumors (RECIST1.1) Target lesions are assessed as Complete Response(CR), Disappearance of all target lesions; Partial Response (PR),30% decrease in the sum of the diameters of target lesions; Progressive Disease (PD), At least a 20% increase (minimum 5 mm) from smallest sum (nadir); Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Nontarget lesions are assessed as Complete Response (CR), Disappearance of all non-target lesions; Non-CR/Non-PD, Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits; Progressive Disease (PD),Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions; Overall Response(OR); PR=CR+non-CR/non-PD,SD=SD+non-PD; PD=PD+presence of any non-target lesions
    measure
    Overall Response Rate (Complete Plus Partial Response) Using RECIST Criteria v1.1
    time Frame
    Up to 1 year
secondary Outcomes
  1. description
    Gr 3, Gr 4 and Gr 5 AEs at least possibly related to study drug
    measure
    Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
    time Frame
    Up to 1 year
  2. description
    Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Descriptive statistics and plotting of data will be used to better understand potential relationships.
    measure
    Levels of Pharmacodynamic Biomarkers
    time Frame
    Pre-dose, at 4-8 hours on day 3 or 20-24 hours on day 4
  3. description
    Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Descriptive statistics and plotting of data will be used to better understand potential relationships.
    measure
    Levels of Predictive Biomarkers
    time Frame
    Up to day 4 of course 1
  4. description
    Estimated in each group by the Kaplan Meier method and differences between groups will be calculated by the log rank test. Hazard ratios for each group will be estimated using the Cox Regression model.
    measure
    Overall Survival
    time Frame
    12 months
  5. description
    Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression (20% increase in the sum of the longest diameter of target lesions or a measurable increase in a non-target lesion, or the appearance of new lesions) or death, whichever occurs first.
    measure
    Progression Free Survival
    time Frame
    Time from start of treatment to time of progression or death, whichever occurs first, assessed at 6 months
  6. description
    Estimated in each group by the Kaplan Meier method and differences between groups will be calculated by the log rank test. Hazard ratios for each group will be estimated using the Cox Regression model.
    measure
    Progression Free Survival
    time Frame
    Time from start of treatment to time of progression or death, whichever occurs first, assessed at 12 months
Full study description
brief Summary
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body. Drugs used in chemotherapy, such as cisplatin, may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA), which in turn stops the tumor from growing. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cisplatin is more effective with or without WEE1 inhibitor MK-1775 in treating patients with head and neck cancer.
detailed Description
PRIMARY OBJECTIVES: I. To compare the overall response rate assess the efficacy of MK-1775 (WEE1 inhibitor MK-1775) in combination with cisplatin to cisplatin alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) as per overall response rate (using Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria version \[v\]1.1). SECONDARY OBJECTIVES: I. Assess secondary measures of efficacy (progression free survival at 6 months and 12 months, overall survival rate at 12 months). II. Assess measures of efficacy by tumor protein (p)53 status. III. Evaluate safety and tolerability. IV. Explore predictive and pharmacodynamic biomarkers. OUTLINE: SAFETY RUN-IN: Patients receive WEE1 inhibitor MK-1775 orally (PO) twice daily (BID) for 5 doses beginning on day 1 and cisplatin intravenously (IV) over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1. ARM II: Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 1 year.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3d93ed9d7245fb096860
      requested nct id
      NCT02196168
      primary nct id
      NCT02196168
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      46bc9f692158656dc0136fdecdf23ccebefde2bac7ee8ea64c726df9d2755da8
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3d93ed9d7245fb096860
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02196168
      occurrences
      1. context exact
        NCT02196168
        end
        11
        exact text
        NCT02196168
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/130/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9c0469461d0207e0959499c6d6fb781a8de21d162d25c1bc01fbaf3dfaa35531
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5d32560211f58e89a161
      requested nct id
      NCT02196168
      primary nct id
      NCT02196168
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      payload sha256
      076adc5195f9bea9f26bf3bb2a828eb0e62d69d365eb07e7cbd1cc2982ad9293
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5d32560211f58e89a161
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02196168
      occurrences
      1. context exact
        NCT02196168
        end
        11
        exact text
        NCT02196168
        start
        0
      offset unit
      unicode_code_points
      query cond
      Metastatic Squamous Neck Cancer With Occult Primary
      query disease state id
      ds-metastatic-squamous-neck-cancer-with-occult-primary
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      source json pointer
      /studies/25/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9c0469461d0207e0959499c6d6fb781a8de21d162d25c1bc01fbaf3dfaa35531
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5d9b7d2d0f20ed83084a
      requested nct id
      NCT02196168
      primary nct id
      NCT02196168
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      5f9847e9e234d8493f2a4b8e18ad6baa94a8b72c997e5da88597a49cf5968e40
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5d9b7d2d0f20ed83084a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02196168
      occurrences
      1. context exact
        NCT02196168
        end
        11
        exact text
        NCT02196168
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/93/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9c0469461d0207e0959499c6d6fb781a8de21d162d25c1bc01fbaf3dfaa35531

    Preserved source evidence · Not medical advice